All In Biotech

Drug Trial Radar · NCT05323981

Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection

A Single Center, Randomized, Double-blind, Parallel Controlled Phase I Trial Comparing the Pharmacokinetics and Safety of Two Specifications of HS627 Injection, a Recombinant Humanized Anti-Human Epidermal Growth Factor Receptor Monoclonal Antibody Injection, With PERJETA After a Single 420mg Intravenous Dose in Healthy Male Subjects

Last checked: Nov 19, 2026Latest source record: Jul 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

180

Actual

Start

Apr 11, 2022

Primary completion

Oct 9, 2022

Study completion Oct 9, 2022

Sponsor

Sponsor type
Industry
First posted
Apr 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the bioequivalence of HS627(2 specifications) with PERJETA in a single intravenous administration in healthy subjects

Conditions

  • Similarity of Pharmacokinetics and Safety

Interventions

  • HS627(210mg/7ml)Drug

    Intravenous drip of 420mg HS627

  • HS627(420mg/14ml)Drug

    Intravenous drip of 420mg HS627

  • PerjetaDrug

    Intravenous drip of 420mg PERJETA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. (AUC0-∞)of HS627(2 specifications) and PERJETATime frame: 85Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.